Trappenburg Marijke C, van Schilfgaarde Muriel, Marchetti Marina, Spronk Henri M, ten Cate Hugo, Leyte Anja, Terpstra Wim E, Falanga Anna
Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
Haematologica. 2009 Jul;94(7):911-8. doi: 10.3324/haematol.13774. Epub 2009 Jun 8.
Most cell types, including blood--and vascular cells, produce microparticles upon activation. Since cellular microparticles are known to be elevated in thromboembolic diseases, we hypothesized a role for microparticles in the pathogenesis of thrombosis in essential thrombocythemia.
In plasma samples from 21 patients with essential thrombocythemia and ten healthy subjects, the levels and the cellular origin of microparticles were determined by flowcytometric analysis, while the microparticle-associated procoagulant activity was measured using a thrombin generation assay.
Patients with essential thrombocythemia had significantly higher numbers of circulating annexin V-positive microparticles than controls (median 4500 vs. 2500x10(6) events/L; p=0.039), including significantly higher numbers of microparticles positive for the platelet marker CD61 (p=0.043), the endothelial markers CD62E (p=0.009) and CD144 (p=0.021), and for tissue factor (p=0.036). CD62E was co-expressed with the platelet marker CD41 on microparticles, suggesting a bilineage origin of such microparticles, which were observed only in patients with risk factors for thrombosis. Patients with essential thrombocythemia had higher plasma levels of mature von Willebrand factor (p=0.045) but similar propeptide levels compared to controls. In thrombin generation analyses, microparticle-rich plasma from patients with essential thrombocythemia had a shorter lag time (p=0.001) and higher peak height (p=0.038) than plasma from controls. Peak height correlated significantly with the total number of microparticles (R=0.634, p<0.001).
Patients with essential thrombocythemia had higher number of circulating microparticles with platelet and endothelial markers, suggesting ongoing platelet and endothelial activation. This was confirmed by an increased level of mature von Willebrand factor, an abnormal mature von Willebrand factor/propeptide ratio, and a hypercoagulable state reflected in thrombin generation. These findings suggest a role for microparticles in thrombosis in essential thrombocythemia.
大多数细胞类型,包括血液和血管细胞,在激活后会产生微粒。由于已知细胞微粒在血栓栓塞性疾病中会升高,我们推测微粒在原发性血小板增多症的血栓形成发病机制中起作用。
在21例原发性血小板增多症患者和10名健康受试者的血浆样本中,通过流式细胞术分析确定微粒的水平和细胞来源,同时使用凝血酶生成试验测量与微粒相关的促凝活性。
原发性血小板增多症患者循环中膜联蛋白V阳性微粒的数量明显高于对照组(中位数分别为4500和2500×10⁶个事件/L;p = 0.039),包括血小板标志物CD61阳性的微粒数量显著更高(p = 0.043)、内皮标志物CD62E阳性的微粒数量显著更高(p = 0.009)、CD144阳性的微粒数量显著更高(p = 0.021)以及组织因子阳性的微粒数量显著更高(p = 0.036)。CD62E与血小板标志物CD41在微粒上共表达,提示此类微粒的双系起源,且仅在有血栓形成危险因素的患者中观察到。原发性血小板增多症患者的血浆中成熟血管性血友病因子水平较高(p = 0.045),但与对照组相比,前肽水平相似。在凝血酶生成分析中,原发性血小板增多症患者富含微粒的血浆与对照组血浆相比,有更短的延迟时间(p = 0.001)和更高的峰值高度(p = 0.038)。峰值高度与微粒总数显著相关(R = 0.634, p < 0.001)。
原发性血小板增多症患者循环中带有血小板和内皮标志物的微粒数量较多,提示血小板和内皮持续激活。成熟血管性血友病因子水平升高、成熟血管性血友病因子/前肽比例异常以及凝血酶生成反映出高凝状态均证实了这一点。这些发现提示微粒在原发性血小板增多症的血栓形成中起作用。